To the full analysis
China Life Insurance stock: growth
2628.HKGrowth only counts when it reaches the bottom line. That is why revenue and earnings for China Life Insurance Company Limited stand side by side here: revenue growing faster than earnings is growth that was bought.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5.3%
per year from 2006 to 2025, per share 4.9%
Earnings (Annual rate)
13.3%
per year from 2006 to 2025, per share 11%
Free cash flow is left out here for banks and insurers: there it mostly reflects movements in loans and deposits and says little about the business. The score leaves it out as well.
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −5.8% | 1.8% | 5.3% |
| Revenue per share | −5.8% | 1.8% | 4.9% |
| Earnings | 25.1% | 16.1% | 13.3% |
| Earnings per share | 25.2% | 16.1% | 11.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
Figures as a table
| Year | Revenue | Earnings |
|---|---|---|
| 2006 | $34.22B | $2.16B |
| 2007 | $42.12B | $4.22B |
| 2008 | $46.96B | $2.87B |
| 2009 | $51.19B | $4.93B |
| 2010 | $58.04B | $5.04B |
| 2011 | $57.46B | $2.75B |
| 2012 | $60.34B | $1.66B |
| 2013 | $63.06B | $3.71B |
| 2014 | $66.26B | $4.83B |
| 2015 | $76.24B | $5.2B |
| 2016 | $81.57B | $2.87B |
| 2017 | $96.88B | $4.84B |
| 2018 | $95.27B | $1.71B |
| 2019 | $110.37B | $8.74B |
| 2020 | $122.47B | $7.54B |
| 2021 | $127.19B | $7.61B |
| 2022 | $123.32B | $4.81B |
| 2023 | $59.46B | $7.68B |
| 2024 | $76.81B | $16.04B |
| 2025 | $90.75B | $23.11B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 8 Nov 2026, previously Strong
- Valuation signal Undervalued since 8 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.